Newer antibiotics designed to treat resistant pathogens may offer superior efficacy and fewer side effects compared to older alternatives. However, access remains severely limited in Asian countries struggling with a high Antimicrobial Resistance (AMR) burden.
This workshop will share the latest research findings from the ADVANCE-ID network and provide a crucial platform for stakeholders from all sectors—including funders, industry, policymakers, healthcare practitioners, and patient advocates—to engage in meaningful interactions and develop action strategies.